Goldman Sachs Group Inc. Sells 481,645 Shares of Recursion Pharmaceuticals, Inc. $RXRX

Key Points

• Goldman Sachs Group Inc. reduced its holdings in Recursion Pharmaceuticals by 24.4%, selling 481,645 shares; the fund owns 1,495,863 shares valued at approximately $7.91 million.
• Research analysts have mixed views on Recursion Pharmaceuticals, with Needham & Company maintaining a "buy" rating and a target price of $8.00, while Morgan Stanley set an "equal weight" rating with a target price of $5.00.
• Recursion Pharmaceuticals reported quarterly earnings with EPS of ($0.41), missing estimates but achieving a revenue of $19.10 million, which was above the consensus of $15.38 million.

Goldman Sachs Group Inc. lowered its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 24.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,495,863 shares of the company's stock after selling 481,645 shares during the quarter. Goldman Sachs Group Inc. owned about 0.37% of Recursion Pharmaceuticals worth $7,913,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of RXRX. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Recursion Pharmaceuticals by 183.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,408,524 shares of the company's stock worth $33,901,000 after buying an additional 4,149,346 shares in the last quarter. ARK Investment Management LLC raised its stake in shares of Recursion Pharmaceuticals by 7.6% in the first quarter. ARK Investment Management LLC now owns 34,815,502 shares of the company's stock worth $184,174,000 after acquiring an additional 2,469,104 shares during the last quarter. Nuveen LLC bought a new position in shares of Recursion Pharmaceuticals in the first quarter worth about $10,118,000. Kinnevik AB publ raised its stake in shares of Recursion Pharmaceuticals by 12.8% during the first quarter. Kinnevik AB publ now owns 13,434,171 shares of the company's stock worth $71,067,000 after buying an additional 1,528,503 shares during the last quarter. Finally, Jump Financial LLC grew its holdings in Recursion Pharmaceuticals by 4,289.8% during the first quarter. Jump Financial LLC now owns 592,353 shares of the company's stock valued at $3,134,000 after purchasing an additional 578,859 shares during the period. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, insider Najat Khan sold 36,599 shares of the company's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $5.52, for a total transaction of $202,026.48. Following the sale, the insider directly owned 668,197 shares of the company's stock, valued at $3,688,447.44. This represents a 5.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 8.43% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

RXRX has been the subject of several research analyst reports. Morgan Stanley started coverage on shares of Recursion Pharmaceuticals in a report on Thursday, July 3rd. They issued an "equal weight" rating and a $5.00 price target for the company. Needham & Company LLC reissued a "buy" rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, September 11th. Two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $7.25.

Recursion Pharmaceuticals Stock Down 0.9%

RXRX stock traded down $0.05 during midday trading on Friday, reaching $4.89. 15,388,507 shares of the company's stock traded hands, compared to its average volume of 23,974,580. Recursion Pharmaceuticals, Inc. has a 52 week low of $3.79 and a 52 week high of $12.36. The company has a quick ratio of 3.58, a current ratio of 3.58 and a debt-to-equity ratio of 0.02. The company has a market cap of $2.12 billion, a price-to-earnings ratio of -2.74 and a beta of 0.91. The firm's fifty day moving average price is $5.30 and its 200-day moving average price is $5.25.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The firm had revenue of $19.10 million during the quarter, compared to the consensus estimate of $15.38 million. Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.The business's revenue was up 33.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.40) EPS. As a group, sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.